NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Hi Hoff.

Are you suggesting they made a mistake in the SAP where it says the 5th secondary endpoint is OS between the 233 vs the 99 randomized to placebo?

Page 15 of the SAP:

Secondary Endpoint #4: Overall Survival (OS) – Comparison between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.

That people cannot understand the basic fact that the arms remain as randomized when evaluating a randomized trial is sad. Probably those with such limited understanding of clinical trials stats 101 should stay out of investing in dev stage biotecs.